In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.50. The company’s shares opened today at ...
GlaxoSmithKline agreed on Sept. 17 to settle out of the first Zantac trial in California, which began this month in Oakland. GSK won two defense verdicts in Illinois earlier this year but faced ...
GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...